Neasa Mc Gettigan

Dr. Neasa Mc Gettigan


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2023 in International Journal of Colorectal Disease
Verified
Journal Article
Open access
PDF file
NGNeasa Mc Gettigan
Neasa Mc Gettigan
KAKathryn Allen
Kathryn Allen
RSReza Saeidi
Reza Saeidi
ATAoibhlinn O’ Toole
Aoibhlinn O’ Toole
KBKaren Boland
Karen Boland
Purpose: Given the substantial risk of treatment failure in inflammatory bowel disease (IBD), adjuvant therapies may play a role in disease management. We aim to carry out a systematic review to examine the effects of structured exercise on the inflammatory response in patients with IBD. Our secondary aim is to examine the effect of structured exercise programmes on body composition given both an increase in visceral obesity and the presence of sarcopenia have deleterious effects on outcomes in IBD. Methods: A systematic review was carried out following the Methodological Expectations of Cochrane Intervention Reviews (MECIR) manual and the Cochrane Handbook for Systematic Reviews of Interventions. Title/Abstract and MeSH Terms were used to search for relevant studies. Results: In total, 1516 records were screened for eligibility, and 148 records were reviewed for eligibility, of which 16 were included and a further 7 studies were identified from hand searching references. Four studies included body composition outcomes, and 14 studies reviewed the inflammatory response to exercise. Conclusion: Further studies of adequate duration are required to include patients with more active disease to demonstrate an inflammatory response to exercise. Body composition measurements including muscle mass and visceral adiposity may play a key role in response to medical therapy in IBD and should be included as exploratory outcomes in future studies. A meta-analysis was not carried out due to the significant heterogeneity amongst studies.

29 January 2021 in International Journal of Colorectal Disease
Verified
Journal Article
Closed access
PDF file
NGNeasa Mc Gettigan
Neasa Mc Gettigan
AAAman Shah Afridi
Aman Shah Afridi
GHGrace Harkin
Grace Harkin
CLCaroline Lardner
Caroline Lardner
SPStephen Patchett
Stephen Patchett
AOAoibhlinn O’toole
Aoibhlinn O’toole

20 August 2025 in Endoscopy
Verified
Journal Article
Closed access
PDF file
GEGianluca Esposito
Gianluca Esposito
MAMiguel Areia
Miguel Areia
HCHey-Long Ching
Hey-Long Ching
NINational Hepatology and Tropical Medicine Research Institute
National Hepatology and Tropical Medicine Research Institute
PGPedro G. Delgado Guillena
Pedro G. Delgado Guillena
AVAndrei M. Voiosu
Andrei M. Voiosu
Upper gastrointestinal (UGI) endoscopy is the mainstay for the diagnosis and staging of precancerous and cancerous conditions of the esophagus, stomach, and duodenum. Despite development of several validated classifications for UGI diseases, endoscopy reports differ between endoscopists and endoscopy departments. This document proposes a standardized high quality UGI endoscopy report, including preprocedural, periprocedural, endoscopic findings, and postprocedural information. Preprocedural details should comprise data on the patient, exam, use of antithrombotic drugs, fasting, and premedication. Periprocedural information should report on medications administered, endoscope used, and the mucosal cleanliness assessment. Endoscopic findings should describe the esophagus, stomach, and duodenum, with any observed abnormalities reported using the most commonly employed classification (provided in the document). Postprocedural details should include data on biopsies and vials, pictures taken during the procedure, and the exam duration. A suggestion for a normal findings report is provided. Standardized reporting could enhance the quality of UGI endoscopy.

14 October 2019 in GastroHep
Verified
Journal Article
Open access
PDF file
NGNeasa Mc Gettigan
Neasa Mc Gettigan
AKAine Keogh
Aine Keogh
OMOrla McCarthy
Orla McCarthy
MMMairead McNally
Mairead McNally
CDCharlene Deane
Charlene Deane
ESEoin Slattery
Eoin Slattery
Background Proactive therapeutic drug monitoring (proactive‐TDM) to optimize maintenance Infliximab (IFX) trough levels prior to loss of response reduces the risk of treatment failure, Inflammatory Bowel Disease‐related surgery and hospitalization when compared with reactive monitoring (reactive‐TDM). Aim The aim of this study is to investigate if proactive‐TDM in a Virtual Biologic Clinic (VBC) improves patient disease control determined by number of hospital admissions, surgeries, patient reported outcome measures (PROMs), and biomarkers of disease activity. Methods We conducted a single centre retrospective Observational Study. Data was collected from commencement of the VBC in June 2016 to September 2017. All IBD patients on IFX in the VBC were included. PROMs were recorded using the IBD‐Control‐8 sub‐score and Visual Analogue Scale (VAS). Results 123 patients were included in the study. A statistically significant improvement in fecal calprotectin was observed with P‐TDM with a p‐value < 0.001. There was a 59% reduction in crisis IBD admissions with the introduction of proactive‐TDM in the VBC (p‐value <0.005). Dose de‐escalations in the first three months of the VBC lead to cost savings of €32,000 per annum. Conclusions The introduction of proactive‐TDM resulted in a significant reduction in hospital admissions, an increase in mean IFX trough levels, a significant improvement in faecal calprotectin and adjustment to therapy in 33% of patients. Proactive‐TDM in the setting of a VBC is an method of managing IBD patients on IFX therapy with the potential for significant cost savings.

10 December 2022 in Gastrointestinal Disorders
Verified
Journal Article
Open access
PDF file
NGNeasa Mc Gettigan
Neasa Mc Gettigan
KAK. Allen
K. Allen
CFC. Foley
C. Foley
SBS. Bennett
S. Bennett
CLC. Lardner
C. Lardner
KBKaren Boland
Karen Boland
Background: Physical activity (PA) in inflammatory bowel disease (IBD) has many potential favourable outcomes including anti-inflammatory effects, improvement in quality of life and improvements in patient body composition. It is recognised that patients with IBD have a significantly decreased exercise tolerance. Aim: 1. To assess physical activity levels, behaviours and barriers to PA in IBD. 2. To assess the likelihood of patients with IBD to engage in a community-based exercise programme. 3. To examine the presence of body image concerns in IBD. Method: Patient surveys were distributed in Beaumont and Connolly Hospitals between October and December 2021. Descriptive statistics, Chi-squared testing and Pearson’s correlations were completed using Minitab. p < 0.05 denoted statistical significance. Results: Data were recorded for a total of 203 patients. Out of all patients, 62% (n = 126) had Crohn’s disease (CD). Over half of the cohort were male (n = 115). Mean weight among females was 75 kg and 83 kg among males. Exercise behaviours: Out of all patients, 71% exercise regularly, on average for 59 min, 3.2 days/week. Walking was the most common form of PA (74%). A post-diagnosis change in exercise behaviour was found in 66% with three-quarters exercising less. The primary barrier to exercise was fatigue (54%). Female gender (p = 0.007) and age < 45 years (p = 0.02) were associated with body image dissatisfaction reported in 62% of patients. Conclusion: These data demonstrate the patient-reported impact of IBD on patient participation in PA. Concerns regarding body image were common and associated with gender and age. A feasibility study of a physician-derived exercise programme in patients with active IBD is underway in Beaumont Hospital to determine the effect on patient response to therapy, inflammation and body composition outcomes (NCT05174754).

5 July 2019 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
NGNeasa Mc Gettigan
Neasa Mc Gettigan
MSMargaret Sheehan
Margaret Sheehan
ESEoin Slattery
Eoin Slattery
To the Editor: